GlassScriptPhysician profile
Palavi Reddy
NPI 1831420090
$4,599.50
in general payments reported to CMS, 2019-2025
33 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $732 · 2023: $772 · 2024: $895 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.94 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $944.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $597.53 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $573.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $312.18 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $310.97 | 2021-2025 | Rexulti, Abilify Mycite |
| Astellas Pharma US INC | $258.04 | 2021-2024 | Veozah |
| Pfizer INC. | $209.93 | 2021-2025 | |
| Axsome Therapeutics, INC. | $173.27 | 2025 | Symbravo, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.86 | 2021-2023 | Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.33 | 2021-2025 | Xifaxan |
| Amgen INC. | $121.95 | 2021-2025 | Otezla, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $84.96 | 2021 | |
| Sanofi-Aventis U.S. LLC | $83.09 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $61.39 | 2021 | |
| Ironshore Pharmaceuticals INC. | $59.07 | 2023-2024 | Jornay Pm |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $46.24 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.17 | 2024 | Caplyta |
| Antares Pharma, INC. | $41.84 | 2025 | Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $35.36 | 2022 | |
| Merck Sharp & Dohme LLC | $34.96 | 2021-2024 | Capvaxive |
| Phathom Pharmaceuticals, INC. | $32.40 | 2025 | Voquezna |
| Nevro Corp. | $30.38 | 2023 | Senza |
| Corcept Therapeutics | $26.55 | 2025 | Korlym |
| Boston Scientific Corporation | $22.60 | 2025 | Axonics |
| Noven Therapeutics, LLC | $21.87 | 2025 | Xelstrym |
| Stryker Corporation | $21.73 | 2025 | Mako |
| Janssen Pharmaceuticals, INC | $21.45 | 2024 | Spravato |
| Actelion Pharmaceuticals US, INC. | $21.01 | 2025 | Uptravi, Opsumit |
| Collegium Pharmaceutical, INC. | $19.34 | 2025 | Jornay Pm |
| Indivior INC. | $19.12 | 2025 | Sublocade |
| Noven Pharmaceuticals, INC. | $17.32 | 2024 | Xelstrym |
| Aytu Biopharma, INC. | $13.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palavi Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.